Lonza acquires Algonomics; Dutch pull Pfizer infant vaccine after deaths;

> Lonza has aquired Belgium's Algonomics, a contract research organisation providing integrated immunogenicity prediction services to support companies in the development of biotherapeutics. Release

> Theravance and Astellas Pharma US announced today the launch of Vibativ (telavancin) in the United States. Release

> Athersys is still seeks funding for its stroke stem cell study. Report

> RXi Pharmaceuticals has appointed Noah Beerman as the company's news President and CEO. He succeeds RXi's co-founder, Tod Woolf, who will continue as a member of RXi's Scientific Advisory Board. Release

> Ireland's Amarin Corporation has appointed John Thero as the company's CFO. Release

> CEL-SCI to conduct first study of LEAPS-H1N1 treatment for hospitalized patients. Release 

> As H1N1 fears mount, experts question chicken egg method of producing vaccines. Report

Pharma News

> Dutch health authorities have yanked a batch of Pfizer's Prevnar following the deaths of three infants. Prevnar report

> Is it time to back off DTC advertising? Report

> Think Big Pharma has been plagued by whistleblower lawsuits lately? You ain't seen nothin' yet, legal eagles say. Article

> Are certain companies getting VIP treatment this flu pandemic? You tell us. Accusations of preferential drug-and-vaccine sales arose almost simultaneously on opposite sides of the globe as South Korean prosecutors raided Roche's offices in Seoul and news broke in New York that two megabanks got flu-shot doses despite a vaccine shortage. Report

> We've kept close tabs on Big Pharma's moves into emerging markets. But as India's Business Standard notes, it's not just Big Pharma that's moving into the subcontinent in a big way. Mid-size companies are shifting production of drugs and active ingredients there as well. Article

And Finally... French scientists who combined gene therapy and cell therapy managed to halt a rare brain disease in two boys. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.